Kyle Malady Sells 667 Shares of DexCom (NASDAQ:DXCM) Stock

Key Points

• Kyle Malady, a director at DexCom, sold 667 shares of the company's stock for approximately $53,933, decreasing his ownership by 2.86% to 22,667 shares worth roughly $1.83 million.
• DexCom reported a 15.2% year-over-year revenue increase with quarterly earnings of $1.16 billion and earnings per share of $0.48, surpassing analyst expectations.
• Analysts have given DexCom a consensus rating of "Moderate Buy" with an average target price of $99.89, while institutional investors hold nearly 98% of the stock.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Kyle Malady sold 667 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

DexCom Price Performance

DXCM traded up $0.40 during midday trading on Tuesday, reaching $78.40. 2,499,621 shares of the company's stock were exchanged, compared to its average volume of 3,922,245. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The stock has a market capitalization of $30.74 billion, a PE ratio of 54.44, a P/E/G ratio of 1.69 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The business's 50-day moving average price is $81.40 and its 200 day moving average price is $78.93.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period last year, the company posted $0.43 EPS. The company's revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. William Blair upgraded DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. Barclays boosted their price objective on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Oppenheimer lowered shares of DexCom from an "outperform" rating to a "market perform" rating in a research report on Monday. UBS Group lifted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Finally, Piper Sandler increased their price target on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $99.89.

Institutional Trading of DexCom

A number of institutional investors and hedge funds have recently made changes to their positions in DXCM. Cim Investment Management Inc. boosted its position in DexCom by 99.7% during the 2nd quarter. Cim Investment Management Inc. now owns 11,163 shares of the medical device company's stock worth $921,000 after purchasing an additional 5,573 shares during the period. B. Riley Wealth Advisors Inc. acquired a new stake in shares of DexCom in the second quarter valued at about $202,000. Liontrust Investment Partners LLP grew its stake in shares of DexCom by 3.7% in the second quarter. Liontrust Investment Partners LLP now owns 103,959 shares of the medical device company's stock valued at $9,075,000 after buying an additional 3,700 shares in the last quarter. Castleark Management LLC purchased a new stake in shares of DexCom during the 2nd quarter valued at about $27,177,000. Finally, CYBER HORNET ETFs LLC acquired a new position in DexCom during the 2nd quarter worth approximately $87,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.